$4,750.00
This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
Highlights
Key topics covered
Valued at nearly $3bn in 2018, the Global Insulin Pumps Market is growing at a fast pace—at a compound annual growth rate (CAGR) of approximately 12%—reaching more than $5bn by 2023.
The market is being driven by strong demand, increasing awareness and adoption of next-generation hybrid closed-loop systems, solid clinical outcomes, and good reimbursement. Market penetration is low, leaving much room for growth.
According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.
There is a strong need for automated continuous insulin delivery as a replacement for cumbersome multiple daily (insulin) injections (“MDI”) using painful pens/needles, which are prone to user error and may leave many type 1 (and insulin-requiring type 2) patients at risk for dangerous complications.
Overall, the insulin pumps market is an evolving market driven by innovation. While Medtronic clearly dominates, technological advances are spurring intense competition. There is a rush to develop even smarter automated hybrid closed-loop systems (artificial pancreas or “AP” systems) driven by “machine learning” or artificial-intelligence-based algorithms. These systems lessen patient burden and autonomously adapt to individuals’ glycemic needs and lifestyles to significantly improve blood glucose control and quality of life for millions of diabetes patients worldwide.
This comprehensive medical market and technology report provides:
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2018-23 time period.
Table of Contents
Executive Summary ……………………………………………………………………………………………… ES-1
i. Diabetes overview………………………………………………………………………………………………..ES-1
ii. Automated insulin pump technology……………………………………………………………………..ES-3
iii. Insulin pumps market………………………………………………………………………………………….ES-4
iv. Competition……………………………………………………………………………………………………….ES-6
v. Methodology………………………………………………………………………………………………………ES-8
vi. Bibliography …………………………………………………………………………………………………….ES-10
Exhibit ES-1: Insulin pumps, global market forecast ($m), 2018-23………………………………… ES-5
1. Diabetes Overview………………………………………………………………………………………………1-1
1.1 Prevalence………………………………………………………………………………………………………… 1-1
1.2 Diabetes defined……………………………………………………………………………………………….. 1-1
1.2.1 Symptoms………………………………………………………………………………………….. 1-2
1.2.2 Complications …………………………………………………………………………………….. 1-4
1.2.3 Diagnosis and treatment………………………………………………………………………. 1-4
1.2.4 Cost of diabetes………………………………………………………………………………….. 1-6
1.3 Bibliography ……………………………………………………………………………………………………… 1-7
2. Automated Insulin Pumps…………………………………………………………………………………….2-1
2.1 Insulin pumps……………………………………………………………………………………………………. 2-3
2.1.1 Insulet Corporation……………………………………………………………………………. 2-12
2.1.2 Medtronic ………………………………………………………………………………………… 2-15
2.1.3 Roche ………………………………………………………………………………………………. 2-30
2.1.4 Tandem Diabetes Care……………………………………………………………………….. 2-31
2.1.5 Valeritas…………………………………………………………………………………………… 2-36
2.2 Emerging artificial pancreas systems………………………………………………………………….. 2-38
2.2.1 Beta Bionics………………………………………………………………………………………. 2-42
2.2.2 Bigfoot Biomedical…………………………………………………………………………….. 2-45
2.2.3 Cellnovo …………………………………………………………………………………………… 2-49
2.2.4 Diabeloop…………………………………………………………………………………………. 2-50
2.2.5 EOFlow…………………………………………………………………………………………….. 2-53
2.2.6 Ypsomed ………………………………………………………………………………………….. 2-54
2.3 Bibliography ……………………………………………………………………………………………………. 2-56
Exhibit 2-1: Leading automated insulin pump brands, by manufacturer…………………………..2-6
Exhibit 2-2: Selected leading automated insulin pumps and hybrid closed-loop (“artificial pancreas”) systems…………………………………………………………………2-7
Exhibit 2-3: The three-step Omnipod insulin delivery process………………………………………2-12
Exhibit 2-4: The new Omnipod DASH………………………………………………………………………2-13
Exhibit 2-5: The MiniMed 670G hybrid closed-loop insulin pump………………………………….2-22
Exhibit 2-6: The Tidepool Loop app for iPhone and Apple Watch ………………………………….2-29
Exhibit 2-7: The new t:slim X2 insulin pump with Basal-IQ technology…………………………..2-32
Exhibit 2-8: The V-Go 24-hour wearable insulin delivery device for type 2 diabetes …………2-37
Exhibit 2-9: Selected companies/startups developing artificial pancreas systems…………….2-39
Exhibit 2-10: Selected artificial pancreas systems under development ……………………………2-40
Exhibit 2-11: The iLet bionic pancreas system…………………………………………………………….2-43
Exhibit 2-12: The Bigfoot Loop artificial pancreas system……………………………………………..2-47
Exhibit 2-13: The Cellnovo Gen 3 mobile-based insulin delivery system…………………………..2-50
Exhibit 2-14: The Diabeloop DBLG1 hybrid closed-loop system ……………………………………..2-52
Exhibit 2-15: The mylife YpsoPump system………………………………………………………………..2-55
3. Market Analysis………………………………………………………………………………………………….3-1
3.1 Insulin pumps market ………………………………………………………………………………………… 3-1
3.1.1 Market forecast: global………………………………………………………………………… 3-1
3.1.2 Market drivers and limiters ………………………………………………………………….. 3-3
3.1.3 Market forecast: by region …………………………………………………………………… 3-6
3.1.4 US market ………………………………………………………………………………………….. 3-7
3.1.5 Five major EU markets…………………………………………………………………………. 3-7
3.1.6 Japanese market…………………………………………………………………………………. 3-7
3.1.7 Rest of the world market……………………………………………………………………… 3-7
3.2 Competitive analysis………………………………………………………………………………………….. 3-8
3.2.1 Market share: global……………………………………………………………………………. 3-8
3.2.2 Market share by region………………………………………………………………………. 3-13
3.3 Financials and corporate growth strategies ………………………………………………………… 3-16
3.3.1 Insulet Corporation……………………………………………………………………………. 3-16
3.3.2 Animas/Johnson & Johnson………………………………………………………………… 3-17
3.3.3 Medtronic ………………………………………………………………………………………… 3-18
3.3.4 Roche ………………………………………………………………………………………………. 3-21
3.3.5 Tandem Diabetes Care……………………………………………………………………….. 3-23
3.3.6 Valeritas…………………………………………………………………………………………… 3-27
3.4 Bibliography ……………………………………………………………………………………………………. 3-28
Exhibit 3-1: Insulin pumps, global market forecast ($m), 2018-23…………………………………….3-3
Exhibit 3-2: Insulin pumps market, forecast sales by region ($m), 2018-23 ………………………..3-6
Exhibit 3-3: Insulin pumps market, global share by supplier, 2018……………………………………3-9
Exhibit 3-4: Insulin pumps market, estimated share by supplier and region, 2018……………..3-15
Exhibit 3-5: Insulet, revenues by segment, FY2018………………………………………………………3-17
Exhibit 3-6: Medtronic, revenues by segment, FY2019 …………………………………………………3-21
Exhibit 3-7: Roche, revenues by segment, FY2018……………………………………………………….3-23
Exhibit 3-8: Tandem Diabetes Care, revenues by segment, FY2018…………………………………3-26
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!